Since 2002, Sinocare has been dedicated to driving changes in the field of blood glucose monitoring with love and technology, and improving the lives of diabetes patients.
1968
The first blood glucose meter came out, allowing patients to self-test their blood sugar and see the results immediately, allowing them to adjust their medication in a timely manner, greatly improving the treatment of diabetes. The American Diabetes Association highly praised the blood glucose meter as "a milestone in the history of diabetes treatment" and listed blood sugar monitoring and drug treatment as one of the five major treatments for diabetes. Currently, blood glucose meters have become the standard method for blood glucose monitoring.
2002
Abnormal blood sugar + time = complications. This highlights the importance of maintaining consistent blood glucose control. At that time, the penetration rate of blood glucose meters among diabetic patients in my country was less than 5%, which was far lower than the 95% in Western developed countries. This would inevitably lead to complications due to insufficient blood glucose monitoring and increase the economic burden on patients' families and society. Sannuo decided to develop and produce blood glucose meters that Chinese diabetics can afford and use, and is committed to promoting the popularization of blood glucose meters in China, hoping to fulfill its social responsibilities.
2004
Sannuo's first SXT-1 blood glucose meter, which is square and round and easy to hold, was launched on the market. At the same time, it developed test strips for automatic siphon loading. This blood glucose meter is characterized by "simple, accurate and affordable" and has been widely received after its launch. Consumer love.
2006
Sannuo's first magazine print advertisement "One-year replacement, ten-year warranty" was a quality commitment Sannuo gave to users at that time. Today, "ten-year replacement, lifetime warranty" is Sannuo's ongoing commitment to users. Time has not only witnessed Sannuo’s rapid development and scale expansion, but also witnessed Sannuo’s service upgrades and continuation of love.
2007
Sannuo officially joined China-Cuba biotechnology cooperation, achieving large-scale exports to Cuba and Latin American markets, which greatly increased Sannuo's total export volume and established the deep friendship between Sannuo and Cuba.
2012
Sannuo was listed on the GEM of Shenzhen Stock Exchange (stock code: 300298), becoming the first stock of blood glucose meters in China. After 10 years of hard work, Sannuo has achieved a leap from "a promoter of the popularization of blood glucose meters in China" to "a leading provider of instant testing products and a high-tech enterprise that has the courage to assume social responsibilities".
2014
Sannuo fully acquired Beijing Jianheng Diabetes Hospital. Jianheng Hospital adheres to the medical concept of "diabetes is preventable, controllable, and treatable" to provide early screening for diabetes and various chronic disease complications and complications, as well as systematic assessment and standardized treatment, helping Sannuo continue to treat chronic diseases such as diabetes. Provide patients with quality products and services to help them improve their quality of life.
2015
After 12 years of painstaking research, Sannuo has brought portable blood glucose meters into thousands of households. However, due to technical reasons, the domestic blood glucose meter hospital market and high-end market have been monopolized by foreign brands. Until 2015, under the joint research of Chief Scientist Mr. Cai Xiaohua and his team, the first real hospital-grade blood glucose meter in China - the Gold Series was developed, breaking the long-standing foreign brands' long-standing expectations for China's blood glucose meter hospital market and high-end market. monopoly.
2015
After 12 years of painstaking research, Sannuo has brought portable blood glucose meters into thousands of households. However, due to technical reasons, the domestic blood glucose meter hospital market and high-end market have been monopolized by foreign brands. Until 2015, under the joint research of Chief Scientist Mr. Cai Xiaohua and his team, the first real hospital-grade blood glucose meter in China - the Gold Series was developed, breaking the long-standing foreign brands' long-standing expectations for China's blood glucose meter hospital market and high-end market. monopoly.
2016
In January 2016, it acquired the American company Trividia Health, entering the leading international blood glucose monitoring camp and becoming the fourth largest blood glucose meter company in the world. In July 2016, it acquired the American PTS Diagnostics diagnostic company and actively expanded its POCT testing business, laying a solid foundation for providing more comprehensive solutions for chronic disease prevention and treatment.
2017
The in-hospital blood glucose management system was launched, achieving a leap from product to service. Improve patients' awareness of diabetes knowledge, improve satisfaction, and achieve seamless blood sugar management between "endocrinology department and non-endocrinology department".
2018
Launch a new brand strategy, upgrade the corporate logo and slogan, and propose to love yourself, love your family, and love others. Every test is love.
2019
"Sannuo Diabetes Charity Foundation" was registered and established. In order to help people with diabetes live a happy and healthy life, the Hunan Province Sino-Diabetes Charity Foundation was established, initiated by Sino-Bio and approved by the Hunan Provincial Department of Civil Affairs. This is the first foundation established specifically for diabetic patients in mainland China.
2019
The non-invasive diabetes risk screening product AGEscan is launched, opening a new entrance to the management of the entire course of diabetes. This product achieves non-invasive screening for diabetes risk by detecting the accumulation level of advanced glycation end products (AGEs) in the human eye lens. Through statistics of massive clinical big data, a diabetes risk assessment model is established to accurately predict future diabetes risk.
2019
Innovative medical device portable multi-index testing equipment, liquid phase iPOCT product iCARE-2000/2100 was released. Adhering to the concept of "making testing easier" and its mission of "providing doctors with appropriate testing equipment and services to help them improve the efficiency of disease diagnosis".
2021
Sannuo Health Diabetes Clinic is open. Adhering to the medical concept of "diabetes is preventable, controllable and reversible", the clinic provides services such as early diabetes screening, systematic assessment, standardized treatment, full-course management inside and outside the hospital, diabetes knowledge education, and psychological counseling. Combining contemporary Internet and artificial intelligence technology, relying on big data to provide more convenient and efficient professional medical services for patients with chronic diseases such as diabetes.
2021
"Sweet Diary" is officially released, hoping that through the form of cartoons, it can help more children and parents with type 1 diabetes rationally understand the disease and master scientific sugar control methods. While promoting parent-child relationships, it can also convey diabetes knowledge in a lively and interesting way. to the public and attract widespread attention.
2022
An investment of RMB 1 billion was invested in the construction of Sannuo Biotech Qingshan Park, which will be completed and put into use. It will realize the large-scale production of iCARE and iCGMS, new products developed globally, and meet the company's R&D and production needs from intelligent manufacturing to smart health development.
2022
On Sugar Day in 2022, a heart-warming song "Born to Love" dedicated to the 140 million sugar lovers will be released online. The lyrics are healing, the melody is brisk, and they revolve around love and companionship. They are eloquent and give people strength. At the same time, they also convey the brand personality of Sannuo: love yourself, love your family, and love others. It’s you, us, and the world who are “born with love”. Pay attention to blood sugar health and care for people with diabetes together.
2023
Sannuo Aikan's continuous glucose monitoring system (CGMs) has been approved for marketing. After ten years of in-depth research and development, it is the world's first CGM product that applies third-generation glucose sensing preparation technology, and has formed independent intellectual property rights that are available globally. The layout of blood glucose monitoring points and lines has been completed to achieve precise management of diabetes and benefit more diabetic patients.
In the future, from data to services, from single indicators to multiple indicators, we will provide better insulin delivery methods, make better use of artificial intelligence, establish a closed loop of "perception + evaluation + intervention", and realize detection parameters based on innovative biosensors. Accurate perception, realizing the interconnection of all things based on the Internet of Things, realizing healthy lifestyle guidance and high-efficiency homogeneous smart medical care comparable to hospitals of the same level based on artificial intelligence, promoting high-quality and efficient management of the entire course of chronic diseases such as diabetes, and reducing the social medical burden , truly benefiting diabetic patients and their families, allowing diabetic patients to live like normal people, and allowing the whole society and all mankind to care for diabetic patients.